Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
NEW YORK, August 29, 2016 /PRNewswire/ --
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
Hemispherx Biopharma
Last Friday, shares in Philadelphia, Pennsylvania headquartered Hemispherx Biopharma Inc. ended the session 0.96% lower at $0.17. The stock recorded a trading volume of 2.30 million shares, which was above its three months average volume of 1.35 million shares. The Company's shares have surged 27.62% in the last month, 38.25% in the previous three months, and 107.38% since the start of this year. The stock is trading 19.84% above its 50-day moving average and 31.97% above its 200-day moving average. Moreover, shares of Hemispherx Biopharma, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the US, have a Relative Strength Index (RSI) of 54.21.
On August 24th, 2016, Hemispherx Biopharma announced that it has received approval of its New Drug Application from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica for commercial sale of rintatolimod (U.S. tradename: Ampligen®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome. The company believes that rintatolimod is the first drug to receive approval for this indication anywhere in the world. The free research report on HEB is available at: http://stock-callers.com/registration/?symbol=HEB
Vascular Biogenics
Or Yehuda, Israel headquartered Vascular Biogenics Ltd's stock fell 4.01%, to close the day at $4.07 with a total volume of 182,564 shares traded. The Company's shares have gained 1.24% in the past month and 11.81% in the previous three months. The stock is trading 2.16% above its 200-day moving average. Additionally, shares of Vascular Biogenics, which is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases, have an RSI of 48.60.
On August 15th, 2016, Vascular Biogenics reported that net loss for Q2 2016 was $3.3 million, or ($0.14) per share, compared to a net loss of $3.0 million, or ($0.15) per share, in Q2 2015. The company's research and development expenses were $2.2 million for Q2 2016, compared to $2.0 million in Q2 2015. The complimentary report on VBLT can be downloaded at: http://stock-callers.com/registration/?symbol=VBLT
BioCryst Pharma
Shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. recorded a trading volume of 627,539 shares at the close of the last trading session. The stock ended the day 1.95% higher at $4.18. The Company's shares have advanced 20.81% in the last one month and 23.67% in the previous three months. The stock is trading above its 50-day moving average by 18.81%. Furthermore, shares of BioCryst Pharmaceuticals, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 52.14.
On August 11th, 2016, BioCryst Pharmaceuticals announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (HAE). APeX-1 is a two part, Phase 2, randomized, double-blind, placebo-controlled dose ranging trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 as a preventative treatment to eliminate or reduce the frequency of angioedema attacks in HAE patients.
On August 12th, 2016, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Visit us today and download our complete research report on BCRX for free at: http://stock-callers.com/registration/?symbol=BCRX
Alnylam Pharma
Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc.'s shares finished Friday's session 2.09% higher at $70.80 with a total volume of 409,614 shares traded. The stock has advanced 3.68% in the last one month and 4.78% over the previous three months. The Company's shares are trading above their 50-day moving average by 7.37%. Furthermore, shares of Alnylam Pharmaceuticals, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 51.00.
On August 02nd, 2016, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock.
On August 4th, 2016, Alnylam Pharmaceuticals reported that revenues were $8.7 million in Q2 2016 and 2015. Revenues for Q2 2016 included $5.4 million from the company's alliance with Sanofi Genzyme and $3.3 million from the company's alliance with The Medicines Company. The company's GAAP net loss for Q2 2016 was $90.1 million, or $1.05 per share, as compared to a net loss of $71.8 million, or $0.85 per share for the same period in the previous year. Get free access to your technical report on ALNY at: http://stock-callers.com/registration/?symbol=ALNY
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article